The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

Nav

General Info

Geography

United States of America (USA)

Coverage type

Country

Time period covered

01/2014 - 12/2017

Data type

Scientific literature

Keywords

COPD

Citation

Authors

Gong Y, Lin C, Jin Y, Chen R

Journal

Can Respir J

Volume

2022

Pages

2878648

Publication year

2022

Suggested citation

Gong Y, Lin C, Jin Y, Chen R. The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. Can Respir J. 2022; 2022: 2878648.

DOI

10115520222878648

PMID

36060827

GHDx Entry last modified on: Mar 25, 2025

Header sites

Search form

Main menu

The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

Nav